20 hours ago
1
georgeclerk
Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug following the sudden departure of the agency’s top biologics regulator, Vinay Prasad.
© FBT Company 2025. All rights are reserved
English (US) ·